Ocumetics Technology Corp. reported encouraging one-month results from all patients in Group 1 of its first-in-human clinical study evaluating the Ocumetics Accommodating Intraocular Lens. The company completed Group 1 surgeries in August and September 2025, with all patients now showing Corrected Distance Visual Acuity ranging from 20/32 to 20/25 in their postoperative exams.
These early results demonstrate significant progress in the development of next-generation vision correction technology that could potentially eliminate the need for corrective lenses. The visual outcomes have met and in some cases exceeded internal expectations at this early stage of recovery, according to company leadership. Dean Burns, President and CEO of Ocumetics, stated that every Group 1 patient is showing steady improvement with visual acuity, reinforcing the company's belief in the transformative potential of the Ocumetics Lens.
The significance of these results lies in the fact that patients in Group 1 began the study with significantly impaired distance vision due to cataracts. Achieving 20/32 or better vision just one month after surgery represents a remarkable recovery pace that highlights the optical quality and stability of the new lens technology. Dr. Doyle Stulting, Chief Medical Officer of Ocumetics, emphasized that these data give the company great confidence as it advances to subsequent patient groups in the clinical trial.
The primary objectives of Group 1 were to confirm safety, evaluate surgical technique, and assess distance vision restoration. The results to date demonstrate that the Ocumetics Lens performs as designed, providing safe implantation and strong optical performance. The lens is designed to fit within the natural lens compartment of the eye and potentially eliminate the need for corrective lenses by allowing the eye's natural muscle activity to shift focus from distance to near, providing clear vision at all distances.
As planning for Group 2 surgeries now underway, the company maintains focus on advancing the technology through subsequent clinical phases. The early success in Group 1 patients suggests the potential for this technology to transform cataract treatment and vision correction approaches globally. Additional updates on the clinical progress are expected in the coming weeks as the company continues its research and development efforts detailed on their corporate website at https://www.ocumetics.com.
